Clinical Trial Results

Showing: All studies [change]
Condition: Cancer Location: Gilbert, Arizona 25 trials found
New Search
Filter
Trial Phase
Study Type
KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)
N/AOBSERVATIONAL Gilbert, Arizona +4 more
RECRUITING
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
PHASE3INTERVENTIONAL Gilbert, Arizona +4 more
RECRUITING
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
PHASE2INTERVENTIONAL Gilbert, Arizona +4 more
RECRUITING
High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer
PHASE3INTERVENTIONAL Gilbert, Arizona +4 more
RECRUITING
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
PHASE3INTERVENTIONAL Huntsville, Alabama +4 more
RECRUITING
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
PHASE3INTERVENTIONAL Huntsville, Alabama +4 more
RECRUITING
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
N/AOBSERVATIONAL Birmingham, Alabama +4 more
RECRUITING
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
PHASE3INTERVENTIONAL Birmingham, Alabama +4 more
RECRUITING
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
PHASE2, PHASE3INTERVENTIONAL Chandler, Arizona +4 more
RECRUITING
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
PHASE3INTERVENTIONAL Anchorage, Alaska +4 more
RECRUITING
Playing Game to Learn About Children's Vaccine Project
NAINTERVENTIONAL Chandler, Arizona
RECRUITING
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
PHASE3INTERVENTIONAL Mobile, Alabama +4 more
RECRUITING
A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer
PHASE3INTERVENTIONAL Homewood, Alabama +4 more
RECRUITING
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
PHASE3INTERVENTIONAL Chandler, Arizona +4 more
RECRUITING
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
PHASE3INTERVENTIONAL Mobile, Alabama +4 more
RECRUITING
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
PHASE3INTERVENTIONAL Chandler, Arizona +4 more
RECRUITING
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
PHASE2INTERVENTIONAL Chandler, Arizona +4 more
RECRUITING
A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer
PHASE4INTERVENTIONAL Birmingham, Alabama +4 more
RECRUITING
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
PHASE3INTERVENTIONAL Chandler, Arizona +4 more
RECRUITING
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
PHASE1, PHASE2INTERVENTIONAL Chandler, Arizona +4 more
RECRUITING
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
PHASE3INTERVENTIONAL Mobile, Alabama +4 more
RECRUITING
Barrigel® PPRT (Post-Prostatectomy Radiation Therapy) Trial
NAINTERVENTIONAL Chandler, Arizona +4 more
RECRUITING
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
PHASE3INTERVENTIONAL Chandler, Arizona +4 more
RECRUITING
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
PHASE3INTERVENTIONAL Birmingham, Alabama +4 more
RECRUITING
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
PHASE2INTERVENTIONAL Birmingham, Alabama +4 more
RECRUITING
Filter Trials
Trial Phase
Study Type